Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJon C. AsterDLDavid Liu

Discussion

Loading...

Member takes

Overview

Analysis shows spatial organization predicts progression-free survival in high-risk smoldering multiple myeloma patients treated with checkpoint inhibitors, suggesting immune dynamics can inform immun

Key Points

  • This study examines how bone marrow spatial architecture impacts treatment duration in smoldering multiple myeloma patients receiving checkpoint inhibitors. Specifically, it explores cellular neighborhoods and immune response correlations with outcomes.
  • Analyzed 15 bone marrow biopsies from high-risk smoldering multiple myeloma patients in a phase II trial of nivolumab combined with lenalidomide and dexamethasone.
  • Evaluated spatially orchestrated cellular niches using imaging mass cytometry with a 32-antibody immune panel.
  • Compared pre- and post-treatment cellular composition and spatial clustering of immune cells.
  • Eight patients showed a median progression-free survival of 33.8 months, with four remaining progression-free at 2 years.
  • Baselines of exhausted CD8 T cells positively correlated with treatment duration, while treatment increased M2-like macrophage proportions.
  • Spatial clustering identified distinct cellular neighborhoods, with CN3 proportions correlating positively with treatment duration.

Cite This Study

Aster et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d689https://doi.org/10.1182/blood-2025-5702
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5186: Spatial single-cell deconvolution of the bone marrow microenvironment to define predictive biomarker for response to immunotherapy in patients treated with a check point inhibitor in smoldering multiple myeloma, phase II trial of nivolumab in combination with lenalidomide and low dose dexamethasone2024
  2. 2Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy2025
  3. 3Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma2025
  4. 4Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  5. 5Abstract LB122: Dynamic interactions of spatially organized tumor, stromal and immune cellular niches predict outcome to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)2026